Sustained delivery of pan-VEGF inhibitor may reduce treatment burden in wet AMD

Sumary of Sustained delivery of pan-VEGF inhibitor may reduce treatment burden in wet AMD:

  • Intravitreal sunitinib malate depot (GB-102): Durability and safety in wet age-related macular degeneration (ALTISSIMO, phase 2b).
  • Back to Healio NEW ORLEANS — Patients with wet age-related macular degeneration experienced a reduced treatment burden with sustained delivery sunitinib, according to a study presented here.
  • The phase 2b ALTISSIMO trial comprised 56 patients who had been diagnosed with wet AMD within 18 months and had at least three prior anti-VEGF injections, including one within the last 21 days.
  • Before the study, patients in the GB-102 1 mg group had an average of 10.1 injections per year.
  • “That difference is even more stark when you look at patients in the extension study: 10.6 injections per year prior to enrollment and 2.8 injections per year on study,” Sheth said.
  • “That’s a 73% reduction in treatment burden for these patients.

Want to know more click here go to source.

From -

Close

Site Language


By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close